Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

50.69 +1.48 (+3.01%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bright Minds Biosciences Inc. - common stock

< Previous 1 2 3 4 5 Next >

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

September 30, 2026

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

May 26, 2026

From Bright Minds Biosciences

Via GlobeNewswire

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Via The Motley Fool

Topics Regulatory Compliance Stocks

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

Via The Motley Fool

Topics Intellectual Property Regulatory Compliance

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗

May 16, 2026

This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

January 09, 2026

From Bright Minds Biosciences

Via GlobeNewswire

The market is filled with gapping stocks in Wednesday's session. ↗

January 07, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

January 06, 2026

Via Chartmill

Why Did DRUG Stock Rocket 51% Today? ↗

January 06, 2026

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

Via Stocktwits

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 06, 2026

Via Chartmill

Why Bright Minds Biosciences Stock Topped the Market on Monday ↗

November 17, 2025

The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.

Via The Motley Fool

Large Patient Population Is Key Driver For Bright Minds' Growth ↗

September 08, 2025

BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025

Via Benzinga

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗

May 07, 2025

Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data.

Via Benzinga

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

March 04, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

February 24, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Biotechs on the Brink: 2 Stocks With Huge Potential

February 14, 2025

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

Via MarketBeat

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

January 23, 2025

Via Benzinga

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

January 07, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

November 21, 2024

From Bright Minds Biosciences

Via GlobeNewswire

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗

November 13, 2024

The reason for the stock's rapid ascent is a mystery.

Via The Motley Fool

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

November 04, 2024

From Bright Minds Biosciences

Via GlobeNewswire

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗

November 04, 2024

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

Via Benzinga

Topics Government

What's Going On With Bright Minds Biosciences Stock? ↗

October 21, 2024

Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly...

Via Benzinga

Topics Artificial Intelligence

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

October 21, 2024

From Bright Minds Biosciences

Via GlobeNewswire

MarketBeat Week in Review – 10/14 - 10/18

October 19, 2024

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

Via MarketBeat

Topics Artificial Intelligence Economy

Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗

October 18, 2024

Via Benzinga

What's Going On With Bright Minds Biosciences Stock Friday? ↗

October 18, 2024

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.

Via Benzinga

Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗

October 18, 2024

Via Benzinga

Topics Stocks

Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗

October 17, 2024

Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials.

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.